Intellia Therapeutics (NTLA) Earnings Date, Estimates & Call Transcripts $7.50 +0.09 (+1.21%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Intellia Therapeutics Earnings Summary Upcoming Q4 Earnings DateMay. 8Before Market OpensEstimatedConsensus EPS (Nov. 7) -$1.37 Actual EPS (Nov. 7) -$1.34 Beat By $0.03 Actual Revenue (Nov. 7) $9.10MIntellia Therapeutics announced Q3 2024 earnings on November 7, 2024, reporting an EPS of -$1.34, which beat analysts' consensus estimates of -$1.37 by $0.03. Quarterly revenue fell 24.1% year-over-year to $9.10 million, above the consensus estimate of $8.28 million. With a trailing EPS of -$5.25, Intellia Therapeutics' earnings are expected to grow next year, from ($5.07) to ($5.00) per share. Q3 2024 Earnings ResourcesQ3 2024 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q) Press Release (8-K)NTLA Upcoming EarningsIntellia Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportPowered by Get Intellia Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intellia Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNTLA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NTLA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Intellia Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20254-$1.40-$1.38-$1.39Q2 20254-$1.42-$1.08-$1.27Q3 20254-$1.62-$1.17-$1.43Q4 20253-$1.94-$1.18-$1.52FY 202515-$6.38-$4.81-$5.60Q1 20263-$1.48-$1.12-$1.33Q2 20263-$1.48-$1.22-$1.32Q3 20263-$1.54-$1.28-$1.44Q4 20263-$2.44-$1.17-$1.65FY 202612($6.94)($4.79)($5.74) Remove Ads Intellia Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/8/2025(Estimated)-------11/7/2024Q3 2024-$1.37-$1.34+$0.03-$1.34$8.28M$9.10M8/8/2024Q2 2024-$1.23-$1.52 -$0.29-$1.10$19.68M$7.00M5/9/2024Q1 2024-$1.35-$1.06+$0.29-$1.00$15.60M$28.94M2/22/2024Q4 2023-$1.47-$1.46+$0.01-$1.46$15.10M-$1.92M11/9/2023Q3 2023-$1.52-$1.38+$0.14-$1.38$12.45M$11.99M8/3/2023Q2 2023-$1.32-$1.40 -$0.08-$1.40$12.08M$13.59M5/4/2023Q1 2023-$1.41-$1.17+$0.24-$1.17$11.76M$12.60M Intellia Therapeutics Earnings - Frequently Asked Questions When is Intellia Therapeutics's earnings date? Intellia Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based off last year's report dates. Learn more on NTLA's earnings history. Did Intellia Therapeutics beat their earnings estimates last quarter? In the previous quarter, Intellia Therapeutics (NASDAQ:NTLA) reported ($1.34) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.37) by $0.03. Learn more on analysts' earnings estimate vs. NTLA's actual earnings. How can I listen to Intellia Therapeutics's earnings conference call? The conference call for Intellia Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Intellia Therapeutics's conference call transcript? The conference call transcript for Intellia Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Intellia Therapeutics generate each year? Intellia Therapeutics (NASDAQ:NTLA) has a recorded annual revenue of $57.88 million. How much profit does Intellia Therapeutics generate each year? Intellia Therapeutics (NASDAQ:NTLA) has a recorded net income of -$481.19 million. NTLA has generated -$5.25 earnings per share over the last four quarters. What is Intellia Therapeutics's EPS forecast for next year? Intellia Therapeutics's earnings are expected to grow from ($5.07) per share to ($5.00) per share in the next year. More Earnings Resources from MarketBeat Related Companies PTGX Earnings Results CPRX Earnings Results MRUS Earnings Results ALVO Earnings Results SRRK Earnings Results CRNX Earnings Results APLS Earnings Results ACAD Earnings Results IMVT Earnings Results VKTX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NASDAQ:NTLA) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTLA Stock Free NTLA Stock Alerts